Short Interest in Ernexa Therapeutics Inc. (NASDAQ:ERNA) Increases By 30.7%

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 138,506 shares, an increase of 30.7% from the December 31st total of 105,975 shares. Based on an average daily trading volume, of 317,861 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.8% of the company’s shares are short sold. Approximately 1.8% of the company’s shares are short sold. Based on an average daily trading volume, of 317,861 shares, the days-to-cover ratio is presently 0.4 days.

Ernexa Therapeutics Trading Up 1.6%

Shares of NASDAQ:ERNA traded up $0.02 during mid-day trading on Monday, hitting $1.24. 26,182 shares of the company traded hands, compared to its average volume of 309,036. The stock has a market cap of $9.73 million, a P/E ratio of -0.41 and a beta of 6.41. The stock has a 50-day moving average price of $1.26 and a two-hundred day moving average price of $1.40. Ernexa Therapeutics has a 12-month low of $1.08 and a 12-month high of $5.55.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its earnings results on Friday, November 7th. The company reported ($0.15) EPS for the quarter.

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. 70.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.